This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thierry Urban, MD; Bernard Lebeau, MD; Claude Chastang, MD, PhD; Pascal Leclerc, MD; Marie José Botto, MD; Joseph Sauvaget, MD

Arch Intern Med. 1993;153(3):384-387.

Abstract
Background
The aim of this study was to analyze the features of the superior vena cava syndrome (SVCS) as initial characteristics in small-cell lung cancer: incidence, dissemination of disease, diagnostic procedures, efficacy and toxic effects of chemotherapy, and median survival in patients with SVCS.

Methods
In a prospective series of 724 patients with biopsy-proved small-cell lung cancer seen during a 6-year period, we reviewed data from patients who also had SVCS.

Results
The incidence of SVCS was 87 of 724 at the time of diagnosis. Initial emergency radiation therapy was not used in these patients. Diagnostic procedures in these patients were not associated with mortality. Rapid initiation of intensive chemotherapy, often with heparin therapy, resulted in complete or partial responses in 81% and no response in 12%; data were not evaluable in 7%. Two of these 87 patients died of aplasia within 4 weeks of chemotherapy. Median survival was not significantly different in the patients with SVCS (median, 42 weeks) and without SVCS (median, 40 weeks). A significant increase in initial brain metastases at the time of diagnosis was observed in patients with SVCS (22% vs 11%).

Conclusions
Intensive chemotherapy is the first line of therapy in small-cell lung cancer. Histologic diagnostic procedures must be performed in patients with SVCS to adapt the treatment to the underlying cause. Initial emergency radiotherapy, before diagnosis or chemotherapy, does not seem to be useful in these patients. Computed tomography of the brain should be performed routinely in patients with SVCS, and prophylactic brain irradiation could be helpful in such patients. Apparently SVCS is not a poor prognostic factor in treated small-cell lung cancer.

(Arch Intern Med. 1993;153:384-387)

Author Affiliations
From the Pulmonary Departments, Hôpital Saint-Antoine, Paris, France (Drs Urban, Lebeau, Leclerc, Botto, and Sauvaget), Centre Hospitalier Général, Saint-Germain en Laye, France (Dr Leclerc), Centre Hospitalier, Creil, France (Dr Botto), and Hôpital Saint Joseph, Paris (Dr Sauvaget); and the Biostatistic and Medical Informatic Department, Hôpital Saint-Louis, Paris (Dr Chastang).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Endovascular Stenting as the First Step in the Overall Management of Malignant Superior Vena Cava Syndrome
Lanciego et al.
Am. J. Roentgenol. 2009;193:549-558.
ABSTRACT | FULL TEXT  

Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Kvale et al.
Chest 2007;132:368S-403S.
ABSTRACT | FULL TEXT  

Use of self-expanding vascular endoprostheses in superior vena cava syndrome
Garcia Monaco et al.
Eur. J. Cardiothorac. Surg. 2003;24:208-211.
ABSTRACT | FULL TEXT  

Stenting as First Option for Endovascular Treatment of Malignant Superior Vena Cava Syndrome
Lanciego et al.
Am. J. Roentgenol. 2001;177:585-593.
ABSTRACT | FULL TEXT  

Vena Caval Obstruction by Tumor
Luckey et al.
NEJM 1994;330:575-575.
FULL TEXT